



NEWS RELEASE  
FOR IMMEDIATE RELEASE

TSX: AMF

## **AMORFIX REPORTS NEW FINDING FOR vCJD BLOOD SCREENING ASSAY AND PROVIDES CORPORATE UPDATE**

**TORONTO, Ontario – September 12, 2008** – Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today reported that its EP-vCJD™ Blood Screening Assay can detect sporadic Creutzfeldt-Jakob Disease (sCJD) prions using brain material spiked into human plasma at the same sensitivity.

“sCJD is the most common form of this brain wasting disease and has a profound impact on health care because of its potential for patient to patient transmission,” noted Dr. Neil Cashman, Chief Scientific Officer of Amorfix. “An antemortem diagnostic test for sCJD would be an important step forward in managing the risk from this disease in health care settings.”

This finding supports Amorfix’s platform technology for detecting aggregated misfolded proteins and expands the potential use of the assay to sCJD. The company is seeking to acquire blood and spinal fluid from sCJD patients to assess whether the assay can be used for antemortem diagnosis of this disease. Sporadic CJD occurs spontaneously in the worldwide population with an estimated 6,000 new cases per year and there are only post-mortem diagnostic tests available.

The company also reported that, other than as a result of generally adverse market conditions, the company is not aware of any reason for the recent decline in its share price. The company continues to advance its business plan for both diagnostic and therapeutic products as outlined in previous announcements.

### **About Amorfix**

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer’s Disease, Parkinson’s Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix’s proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix’s lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

*This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are*

*cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

- 30 -

**For more information, please contact:**

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	---